Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation
Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation
Objective To investigated the safety and efficacy of donor-derived CD 19+or sequential CD 19+CD22+chimeric antigen receptor T-cell(CAR-T)therapy in patients with B-cell acute lymphoblastic leukemia(B-ALL)after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Methods The data of 22 patients with B-ALL who relapsed after allo-HSCT and who underwent donor-derived CAR-T therapy at the Zhujiang Hospital of Southern Medical University and the 920th Hospital of Joint Logistics Support Force of the People's Liberation Army of China from September 2015 to December 2022 were retrospectively analyzed.The primary endpoint was overall survival(OS),and the secondary endpoints were event-free survival(EFS),complete remission(CR)rate,and Grade 3-4 adverse events.Results A total of 81.82％(n=18)of the 22 patients achieved minimal residual disease-negative CR after CAR-T infusion.The median follow-up time was 1037(95％CI 546-1509)days,and the median OS and EFS were 287(95％CI 132-441)days and 212(95％CI 120-303)days,respectively.The 6-month OS and EFS rates were 67.90％(95％CI 48.30％-84.50％)and 58.70％(95％CI 37.92％-79.48％),respectively,and the 1-year OS and EFS rates were 41.10％(95％CI 19.15％-63.05％)and 34.30％(95％CI 13.92％-54.68％),respectively.Grade 1-2 cytokine release syndrome occurred in 36.36％(n=8)of the patients,and grade 3-4 occurred in 13.64％of the patients(n=3).Grade 2 and 4 graft-versus-host disease occurred in two patients.Conclusion Donor-derived CAR-T therapy is safe and effective in patients with relapsed B-ALL after allo-HSCT.
维普
万方数据